Page 1

4 February 2026 Futura Medical plc ("Futura", "the Group" or the "Company") Trading Update Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and globalcommercialisation of innovative and clinically proven sexual health products, is pleased to provide an unaudited trading update for the yearended 31 December 2025 (FY25). The Company now expects to deliver FY25 revenue of £1.7 million, ahead of previously guided management expectations*. Additionally, netcash at year end was £3.4 million following the successful £2.75 million fundraise in November 2025. As previously announced, under theCompany's existing agreement with Haleon and subject to the granting of a U.S. patent for Eroxon, the Company expects to trigger amilestone payment from Haleon of US$2.5 million during H1 2026; in addition, the Company expects to receive a tax credit refund forFY2025 of approximately £0.3 million. The Company's existing cash resources including the net proceeds of the fundraise in November 2025, combined with the expected taxcredit refund for the 2025 financial year, the US patent milestone payment from Haleon and proceeds from ongoing sales of Eroxon, areexpected to provide the Company with a cash runway to December 2026, which is in line with prior statements. As previously announced, the Board is undertaking a strategic review of the business and its operations which is expected to conclude in Q12026. The outcomes of the review will be published in the Company's Full Year Results which are expected to be released mid-April 2026. *On 19th September 2025, the Company disclosed that it expected to deliver revenue between £1.3 million and £1.4 million for FY25 The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market AbuseRegulation (EU) No. 596/2014 as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019.  Contacts: Futura Medical plc Alex DugganChief Executive OfficerAngela HildrethFinance Director and COO investor.relations@futuramedical.com+44 (0)1483 685 670www.futuramedical.com Panmure LiberumNominated Adviserand Broker Emma Earl, Will Goode, MarkRogers (Corporate Finance) +44 (0)20 3100 2000 Turner PopeInvestments (TPI)Ltd - Broker Guy McDougall, Andrew Thacker +44 (0) 20 3657 0050 Alma StrategicCommunications Rebecca Sanders-Hewett, SamModlin, Sarah Peters +44 (0)20 3405 0205futura@almastrategic.com Notes to Editors: Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically deliveredgel formulations in sexual health products. Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult agebrackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% ofwomen experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronicallyunderserved. Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is theonly topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date. Multiple distributionpartnerships are in place for Eroxon, across major consumer markets. The WSD4000 is a prototype product designed for the symptoms of impaired sexual response and function in women. There is currently noregulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be aneffective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire,arousal and lubrication.